313:
149:
Timmerman, John; Lavie, David; Johnson, Nathalie A.; Avigdor, Abraham; Borchmann, Peter; Andreadis, Charalambos; Bazargan, Ali; Gregory, Gareth; Keane, Colm; Inna, Tzoran; Vucinic, Vladan; Zinzani, Pier Luigi; Zhang, Hong; Pillai, Pallavi; Marinello, Patricia; Herrera, Alex
Francisco (1 June 2022).
107:
Timmerman, John; Lavie, David; Johnson, Nathalie A.; Avigdor, Abraham; Borchmann, Peter; Andreadis, Charalambos; Bazargan, Ali; Gregory, Gareth P.; Keane, Colm; Tsoran-Rosenthal, Inna; Vucinic, Vladan; Zinzani, Pier Luigi; West, Rachel
Marceau; Pillai, Pallavi; Nahar, Akash; Herrera, Alex F. (15
271:
Garralda, Elena; Sukari, Ammar; Lakhani, Nehal J.; Patnaik, Amita; Lou, Yanyan; Im, Seock-Ah; Golan, Talia; Geva, Ravit; Wermke, Martin; De Miguel, Maria; Palcza, John; Jha, Sujata; Chaney, Marya F.; Healy, Jane Anne; Falchook, Gerald Steven (20 May 2021). "A phase 1 first-in-human study of the
235:
Rha, Sun Young; Miller, Wilson H.; de Miguel, María José; Im, Seock-Ah; Lugowska, Iwona; Wermke, Martin; Kotani, Daisuke; Bauer, Todd
Michael; Takashima, Atsuo; Palcza, John; Chaney, Marya F.; Dobrenkov, Konstantin; Garralda, Elena (1 February 2023). "Phase 1 trial of the anti-LAG3 antibody
185:
Garralda, E.; Sukari, A.; Lakhani, N.J.; Patnaik, A.; Lou, Y.; Im, S.-A.; Golan, T.; Geva, R.; Wermke, M.; de Miguel, M.; Palcza, J.; Jha, S.; Chaney, M.; Abraham, A.K.; Healy, J.; Falchook, G.S. (December 2022).
150:"Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study".
110:"Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment"
188:"A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer"
378:
354:
272:
anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer".
373:
62:
49:
383:
35:
388:
347:
83:
340:
289:
253:
167:
131:
217:
324:
281:
245:
207:
199:
159:
121:
17:
212:
187:
87:
285:
163:
367:
293:
257:
171:
135:
43:
249:
320:
203:
29:
126:
109:
221:
312:
236:
favezelimab plus pembrolizumab in advanced gastric cancer".
328:
61:
56:
42:
28:
23:
348:
8:
16:
355:
341:
211:
125:
99:
15:
7:
309:
307:
82:is a fixed-dose combination of two
379:Drugs developed by Merck & Co.
327:. You can help Knowledge (XXG) by
14:
286:10.1200/JCO.2021.39.15_suppl.3584
164:10.1200/JCO.2022.40.16_suppl.7545
311:
250:10.1200/JCO.2023.41.4_suppl.394
1:
274:Journal of Clinical Oncology
238:Journal of Clinical Oncology
204:10.1016/j.esmoop.2022.100639
152:Journal of Clinical Oncology
405:
306:
90:to treat various cancers.
127:10.1182/blood-2022-166670
120:(Supplement 1): 768–770.
80:Favezelimab/pembrolizumab
18:Favezelimab/pembrolizumab
374:Combination cancer drugs
323:-related article is a
384:Monoclonal antibodies
84:monoclonal antibodies
52:monoclonal antibody
38:monoclonal antibody
20:
389:Pharmacology stubs
280:(15_suppl): 3584.
158:(16_suppl): 7545.
336:
335:
77:
76:
396:
357:
350:
343:
315:
308:
298:
297:
268:
262:
261:
244:(4_suppl): 394.
232:
226:
225:
215:
182:
176:
175:
146:
140:
139:
129:
108:November 2022).
104:
21:
19:
404:
403:
399:
398:
397:
395:
394:
393:
364:
363:
362:
361:
304:
302:
301:
270:
269:
265:
234:
233:
229:
184:
183:
179:
148:
147:
143:
106:
105:
101:
96:
73:
70:Investigational
12:
11:
5:
402:
400:
392:
391:
386:
381:
376:
366:
365:
360:
359:
352:
345:
337:
334:
333:
316:
300:
299:
263:
227:
177:
141:
98:
97:
95:
92:
75:
74:
72:
71:
67:
65:
59:
58:
54:
53:
46:
40:
39:
32:
26:
25:
24:Combination of
13:
10:
9:
6:
4:
3:
2:
401:
390:
387:
385:
382:
380:
377:
375:
372:
371:
369:
358:
353:
351:
346:
344:
339:
338:
332:
330:
326:
322:
317:
314:
310:
305:
295:
291:
287:
283:
279:
275:
267:
264:
259:
255:
251:
247:
243:
239:
231:
228:
223:
219:
214:
209:
205:
201:
198:(6): 100639.
197:
193:
189:
181:
178:
173:
169:
165:
161:
157:
153:
145:
142:
137:
133:
128:
123:
119:
115:
111:
103:
100:
93:
91:
89:
86:developed by
85:
81:
69:
68:
66:
64:
60:
55:
51:
47:
45:
44:Pembrolizumab
41:
37:
33:
31:
27:
22:
329:expanding it
321:pharmacology
318:
303:
277:
273:
266:
241:
237:
230:
195:
191:
180:
155:
151:
144:
117:
113:
102:
79:
78:
63:Legal status
57:Legal status
30:Favezelimab
368:Categories
94:References
294:236349131
258:256265890
192:ESMO Open
172:249445835
136:260785891
222:36493599
213:9832734
292:
256:
220:
210:
170:
134:
319:This
290:S2CID
254:S2CID
168:S2CID
132:S2CID
114:Blood
88:Merck
48:Anti-
36:LAG-3
34:Anti–
325:stub
218:PMID
50:PD-1
282:doi
246:doi
208:PMC
200:doi
160:doi
122:doi
118:140
370::
288:.
278:39
276:.
252:.
242:41
240:.
216:.
206:.
194:.
190:.
166:.
156:40
154:.
130:.
116:.
112:.
356:e
349:t
342:v
331:.
296:.
284::
260:.
248::
224:.
202::
196:7
174:.
162::
138:.
124::
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.